MANGOCEUTICALS, INC.

false 0001938046 0001938046 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 29, 2026 MANGOCEUTICALS, INC. (Exact name of registrant as specified in its charter) Texas 001-41615 87-3841292 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 17130 N. Dallas Parkway , Suite 240 Dallas , Texas 75248 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (214) 242-9619 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq Stock Market LLC (Nasdaq Capital Market) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. Private Placement Subscriptions On June 29, 2026, Mangoceuticals, Inc. (the “ Company ”, “ we ” and “ us ”) entered into a Subscription Agreement with an accredited investor (the “ Investor ”), pursuant to which the Investor purchased 850,000 shares of restricted common stock from the Company, for $0.32 per share, or a total of $272,000. The Subscription Agreement included customary representations and warranties of the Investor and the Company and includes piggyback registration rights for a period of one year following the dates of the subscription. The description of the Subscription Agreement above is not complete and is qualified in its entirety by the full text of the form of Subscription Agreement, a copy of which is attached hereto as Exhibit 10.1 , and which is incorporated by reference into this Item 1.01 in its entirety by reference. Item 3.02. Unregistered Sales of Equity Securities. The information set forth in Item 1.01 above is incorporated by reference into this Item 3.02 in its entirety. The Company claims an exemption from registration for the issuance of the shares to the Investor (as discussed in Item 1.01 , above), pursuant to Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act of 1933, as amended (the “ Securities Act ”), since the offer and sale of such shares did not involve a public offering and the recipient was an “ accredited investor ” and had access to similar information as would be included in a registration statement under the Securities Act. The securities were offered without any general solicitation by us or our representatives. No underwriters or agents were involved in the foregoing offers and sales and we paid no underwriting discounts or commissions. The securities are subject to transfer restrictions, and the securities contain an appropriate legend stating that such securities have not been registered under the Securities Act and may not be offered or sold absent registration or pursuant to an exemption therefrom. The securities were not registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. Item 9.01 Exhibits. (d) Exhibits. Exhibit No. Description 10.1* Form of Common Stock Subscription Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). * Filed herewith. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: July 2, 2026 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer